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Abstract
Background: Endogenous estrogens and estrogen metabolites play an important role in the pathogenesis and
development of human breast, endometrial, and ovarian cancers. Increasing evidence also supports their
involvement in the development of certain lung, colon and prostate cancers.
Methods: In this study we systemically surveyed endogenous estrogen and estrogen metabolite levels in each of
the NCI-60 human tumor cell lines, which include human breast, central nerve system, colon, ovarian, prostate,
kidney and non-small cell lung cancers, as well as melanomas and leukemia. The absolute abundances of these
metabolites were measured using a liquid chromatography-tandem mass spectrometry method that has been
previously utilized for biological fluids such as serum and urine.
Results: Endogenous estrogens and estrogen metabolites were found in all NCI-60 human tumor cell lines and
some were substantially elevated and exceeded the levels found in well known estrogen-dependent and estrogen
receptor-positive tumor cells such as MCF-7 and T-47D. While estrogens were expected to be present at high
levels in cell lines representing the female reproductive system (that is, breast and ovarian), other cell lines, such as
leukemia and colon, also contained very high levels of these steroid hormones. The leukemia cell line RMPI-8226
contained the highest levels of estrone (182.06 pg/106 cells) and 17b-estradiol (753.45 pg/106 cells). In comparison,
the ovarian cancer cell line with the highest levels of these estrogens contained only 19.79 and 139.32 pg/106 cells
of estrone and 17b-estradiol, respectively. The highest levels of estrone and 17b-estradiol in breast cancer cell lines
were only 8.45 and 87.37 pg/106 cells in BT-549 and T-47D cells, respectively.
Conclusions: The data provided evidence for the presence of significant amounts of endogenous estrogens and
estrogen metabolites in cell lines not commonly associated with these steroid hormones. This broad discovery of
endogenous estrogens and estrogen metabolites in these cell lines suggest that several human tumors may be
beneficially treated using endocrine therapy aimed at estrogen biosynthesis and estrogen-related signaling
pathways.
Background
Endogenous estrogens and estrogen metabolites (EMs)
have long been associated with carcinogenesis and devel-
opment of several hormone-dependent human carcino-
mas, such as breast, endometrial, and ovarian cancers
[1,2]. Increasing evidence suggests that these metabolites
may be involved in the pathogenesis and development of
human lung [3,4] and colon [5] cancers as well as prostate
cancer [6]. Historically, the major primary function of 17b
estradiol (E2) was the development of female secondary
sexual characteristics and regulation of reproductive func-
tion. Today it is recognized that E2 exerts some effect on
almost every organ in the body [7]. The effects of E2 and
other estrogens have expanded to include roles in neurolo-
gical function [8], retinal degenerative disease [9], cardio-
vascular health [10], and even sleep regulation [11].
Given the well documented mitogenic and possible gen-
otoxic nature of endogenous estrogens and EMs [2,12,13],
potential involvement of EMs in the carcinogenesis of
an even greater variety of human tumors is conceivable.
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For example, some studies have suggested that estrogen
may be involved in the development of skin cancer as skin
keratinocytes possess estrogen receptors (ERs) [14], and
oral contraceptives and hormone therapy decrease acne
[15] and skin aging [16], respectively. Epidemiological stu-
dies examining associations between hormone therapy
and melanoma risk have not been entirely conclusive,
although some studies have shown a link between hor-
mone use and increased risk of melanoma [17,18]. Epide-
miologically, estrogens have also been linked to colon
cancer, as men are more likely to develop this disease and
hormone replacement therapy has been shown to reduce
the risk of this cancer in women [19].
Owing to the pervasive nature of the functions of EMs,
their effect on cancers may be more pronounced than pre-
viously thought. Determining EM roles in various cancers
requires a lot of information, including tumor receptor
status, aromatase activities, and the levels of these com-
pounds within cells. Towards this aim, we systemically
surveyed human tumor cell EM levels by using NCI-60
human tumor cell lines, including human breast, central
nervous system (CNS), colon, ovarian, prostate, kidney,
melanoma, leukemia, and non-small cell lung cancers.
Detailed EM profiles in NCI-60 human tumor cell lines
are summarized and reported in this manuscript.
Materials and methods
Reagents and materials
Cell pellets from NCI-60 human tumor cell lines were
obtained from Developmental Therapeutics Program,
NCI/NIH. Fifteen estrogens and EMs, including estrone
(E1), estradiol (E2), estriol (E3), 16-epiestriol (16-epiE3),
17-epiestriol (17-epiE3), 16-ketoestradiol (16-ketoE2),
16a-hydroxyestrone (16a-OHE1), 2-methoxyestrone
(2-MeOE1), 4-methoxyestrone (4-MeOE1), 2-hydroxyes-
trone-3-methyl ether (3-MeOE1), 2-methoxyestradiol
(2-MeOE2), 4-methoxyestradiol (4-MeOE2), 2-hydro-
xyestrone (2-OHE1), 4-hydroxyestrone (4-OHE1), and
2-hydroxyestradiol (2-OHE2) were obtained from Stera-
loids, Inc. (Newport, RI, USA). Stable isotope-labeled




(13C6-E1) were purchased from Cambridge Isotope
Laboratories, Inc. (Andover, MA, USA); estriol-2,4,17-d3
(d3-E3), 2-hydroxyestradiol-1,4,16,16,17-d5 (d5-2-OHE2),
and 2-methoxyestradiol-1,4,16,16,17-d5 (d5-2-MeOE2),
were obtained from C/D/N Isotopes, Inc. (Pointe-Claire,
Quebec, Canada). 16-Epiestriol-2,4,16-d3 (d3-16-epiE3)
was purchased from Medical Isotopes, Inc. (Pelham,
NH, USA). All EM and SI-EM analytical standards have
reported chemical and isotopic purity ≥98%, and were
used without further purification. Dichloromethane,
methanol and formic acid were obtained from EM
Science (Gibbstown, NJ, USA). Glacial acetic acid,
sodium bicarbonate, and L-ascorbic acid were purchased
from JT Baker (Phillipsburg, NJ, USA) and sodium
hydroxide and sodium acetate were purchased from
Fisher Scientific (Fair Lawn, NJ, USA). Dansyl chloride
and acetone were purchased from Aldrich Chemical Co.
(Milwaukee, WI, USA). All chemicals and solvents used
in this study were HPLC or reagent grade unless other-
wise noted.
Preparation of stock and working standard solutions and
calibration standards
Stock solutions of EMs and SI-EMs were each prepared
at 80 μg/ml by dissolving 2 mg of the estrogen powders
in methanol with 0.1% L-ascorbic acid to a final volume
of 25 ml in a volumetric flask. The stock solutions are
stable for at least two months while stored at -20°C.
Stock solutions were analyzed at the beginning of each
analysis to verify no time-dependent degradation of the
EM and SI-EM standards had occurred. Working stan-
dards of EMs and SI-EMs at 8 ng/ml were prepared by
dilutions of the stock solutions using methanol with
0.1% L-ascorbic acid.
MCF-10A cell lysate with no detectable levels of EMs
was employed for preparation of calibration standards
and quality control samples. Each calibration standard
contained lysate from approximately 50,000 MCF-10A
cells and was prepared by adding 2 μl of the SI-EM
working internal standard solution (16 pg of each SI-
EM) to various volumes of the EM working standard
solution. These calibration standards typically contain
0.2 to 200 pg of each EM in 0.5 ml of MCF-10A cell
lysate and were assayed in duplicate. The calibration
standards cover three orders of magnitude.
Sample preparation procedure
Samples were prepared and analyzed following a pre-
viously published method [20,21]. Briefly, each tumor
cell pellet contained approximately 1 million cells. They
were first suspended in 2 ml ice cold 12.5 mM
NH4HCO3 solution. Cell lyses were prepared by tip
sonication on ice in five cycles of 10-second pulses and
10-second breaks followed by 30-minute water bath
sonication. To 0.5 ml of each cell lysate, 0.5 ml of
freshly prepared 0.15 M sodium acetate buffer (pH 4.6)
containing 16 pg of each SI-EM and 2 mg of L-ascorbic
acid was added. Samples then underwent slow inverse
extraction at 8 rpm (RKVSD™, ATR, Inc., Laurel, MD,
USA) with 5 ml dichloromethane for 30 minutes. After
extraction, the organic solvent portion was transferred
into a clean glass tube and evaporated to dryness at 60°
C under nitrogen gas (Reacti-Vap III™, Pierce, Rock-
ford, IL, USA).
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To each dried sample, 32 μl of 0.1 M sodium acetate
buffer (pH at 9.0) and 32 μl of dansyl chloride solution
(1 mg/ml in acetone) were added. After vortexing, the
sample was heated at 60°C (Reacti-Therm III™ Heating
Module, Pierce, Rockford, IL, USA) for 10 minutes to
form the EM and SI-EM dansyl derivatives (EM-Dansyl
and SI-EM-Dansyl, respectively). Calibration standards
and quality control samples were hydrolyzed, extracted,
and derivatized following the same procedure used for
unknown cell samples. After derivatization, all samples
were analyzed by capillary liquid chromatography (LC)-
tandem mass spectrometry (MS2).
Liquid chromatography-tandem mass spectrometry
LC-MS2 analysis was performed using an Agilent 1200
series nanoflow LC system (Agilent Technologies, Palo
Alto, CA, USA) coupled to a TSQ™ Quantum Ultra tri-
ple quadrupole mass spectrometer (Thermo Electron,
San Jose, CA, USA). The LC separation was carried out
on a 150 mm long × 300 μm internal diameter column
packed with 4 μm Synergi Hydro-RP particles (Phenom-
enex, Torrance, CA, USA) and maintained at 40°C. A total
of 8 μl of each sample was injected onto the column. The
mobile phase, operating at a flow rate of 4 μl/minute, con-
sists of methanol as solvent A and 0.1% (v/v) formic acid
in water as solvent B. A linear gradient from 72 to 85%
solvent B in 75 minutes was employed for separation of
EMs and SI-EMs. The mass spectrometry conditions were:
source, ESI; ion polarity,positive; spray voltage, 3200 V;
sheath and auxiliary gas, nitrogen; sheath gas pressure, 10
arbitrary units; ion transfer capillary temperature, 270 °C;
scan type, selected reaction monitoring; collision gas,
argon; collision gas pressure, 1.5 mTorr; scan width, 0.7 u;
scan time, 0.30 s; Q1 peak width, 0.70 u full-width half-
maximum (FWHM); Q3 peak width, 0.70 u FWHM. The
optimized selected reaction monitoring conditions for the
protonated molecules [MH]+ of EM-Dansyl and SI-EM-
Dansyl were similar to those previously described [9,10].
Quantification of estrogen metabolites
Quantification of EMs was carried out using Xcalibur™
Quan Browser (Thermo Electron) as previously described
[20,21]. Briefly, calibration curves for the each EM were
constructed by plotting EM-Dansyl/SI-EM-Dansyl peak
area ratios obtained from calibration standards versus
amounts of the EM injected on the column and fitting
these data using linear regression with 1/X weighting. The
amounts of EMs in cells were then interpolated using this
linear function. Based on their similarity of structures and
retention times, 13C6-E2 was used as the internal standard
for E2;
13C6-E1 for E1; d3-E3 for E3, 16-ketoE2, and 16a-
OHE1; d3-16-epiE3 for 16-epiE3 and 17-epiE3; d5-2-
MeOE2 for 2-MeOE2, 4-MeOE2, 2-MeOE1, 4-MeOE1, and
3-MeOE1; d5-2-OHE2 for 2-OHE2, 2-OHE1, and 4-OHE1.
Results and discussion
The levels of endogenous estrogens and EMs were mea-
sured in the NCI-60 cell lines, which comprise breast (n =
5), CNS (n = 6), colon (n = 7), leukemia (n = 6), melanoma
(n = 9), non-small cell lung (n = 9), ovarian (n = 9), pros-
tate (n = 2), and renal (n = 8) cancers. This study focused
on measuring only the unconjugated, active forms of the
EMs. Glucoronidated and sulfated forms of the EMs were
not included in the analysis. All NCI-60 human tumor cell
lines showed significant levels of E1, E2, 16-ketoE2, 16a-
OHE1, E3, 2-MeOHE1, 2-MeOHE2, and 2-OHE1. The
chromatograms showing the eight quantified endogenous
EMs for an ovarian (SK-OV-3) and colon cancer cell line
(HCC-2998) are shown in Figure 1. The peaks were gener-
ally well resolved and had good signal-to-noise ratios for
all cell lines analyzed. While undetectable in all the others,
2-OHE1 was found in the non-small cell lung cancer cell
line NCI-H460.
Within the same type of cancer, different tumor cell
lines had substantially different levels of EMs (Table 1).
For example, SF-539 and SNB-75 cells produced greater
amounts of estrogens than the other CNS lines tested.
HCC-2998 colon cancer cells, RMPI-8226 leukemia
cells, SK-MEL-28, UACC-257, UACC-62, MALME-3M
melanoma cells, EKVX, NCI-H23, NCI-H226 non-small
cell lung (NSCL) cancer cells, OVCAR-4, OVCAR-5,
SK-OV-3 ovarian cancer cells, and CAKI-1 renal cancer
cells all produced greater amounts of estrogens than the
other cell lines within their category. Furthermore,
estrogen levels in these tumor cell lines were substan-
tially elevated and even exceeded the levels typically
found in well characterized estrogen-dependent and ER-
positive tumor cells such as MCF-7 and T-47D.
Within each tumor cell line, E2 was by far the most
abundant unconjugated estrogen followed by E1 and 2-
OHE2 (Table 1). For the five breast cancer cell lines, E2
represented 75 to 85% of the total amount of unconju-
gated EMs measured. For six of the ovarian cancer cell
lines, E2 represented 77 to 87% of the total estrogen con-
tent, while this percentage was only 62% for OVCAR-3
cells. T-47D and MCF-7 cells are both estrogen-dependent
and ER-positive human breast cancer cells and have E2
levels at 87 and 81 pg/106 cells, which accounted for 85%
and 82% of their total unconjugated estrogens, respec-
tively. MDA-MB-231 is an estrogen-independent, ER-
negative, HER2-positive human breast cancer cell line and
still has E2 levels of about 37 pg/10
6 cells, which accounts
for about 75% of its total unconjugated estrogen levels.
The cell lines with the highest E2 levels are shown in
Figure 2a. Although estrogens are commonly associated
with breast cancer, none of these cell lines were among
those that contained the highest levels of E2. Consistent
with evidence linking estrogen levels with cancers of the
reproductive system in general, three ovarian cancer cell
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lines (OVCAR-4, OVCAR-5, and SK-OV-3) were
amongst those with the highest E2 levels. OVCAR-4 and
-5 are both ERa-negative, ERb-positive ovarian cell lines
who’s growth is insensitive to E2 treatment [22]. While
SK-OV-3 cells do express ERa, their growth is also
insensitive to treatment with E2 [22]. The leukemia cell
line RMPI-8226 possessed the highest levels of E2 (753
pg/106 cells). In fact, its E2 levels were more than 3.5-
fold higher than the colon cell line HCC-2998, which
contained the next highest level of E2 (209 pg/106 cells).
This result correlates with a previous study showing
that RMPI-8226 cells possess the highest ER levels com-
pared to other leukemia and myeloid cell lines tested
[23]. Previous studies have shown that the HL60 leuke-
mia cell line possesses ERs and its proliferation is sensi-
tive to E2 treatment. When the cells are maintained in
a medium containing physiological concentrations
(10-9 M, 10-8 M, 10-7 M) of E2, cell growth is stimulated;
however, pharmacological concentrations (10-6 M) of E2
inhibit their growth [24]. Adding tamoxifen inhibited
the stimulating effect of the estrogens by binding to and
blocking the ER. The effect of estrogen was therefore
associated with the presence of ERs in the human leuke-
mic cell line HL60 and may be important in the prolif-
eration of other leukemic cell lines.
Cell lines with the lowest E2 levels are shown in
Figure 2b. Four of these were colon cell lines (HCT-116,
HCT-15, KM12, and SW-620). Their E2 levels ranged
from 1.31 to 12.25 pg/106 cells. To put into perspective
the range of E2 values found in all the cell lines, SW-
620 colon cells contained almost 575-fold less E2 than
RMPI-8226 cells. The finding that colon cell lines gener-
ally contain low levels of E2 is consistent with a previous
study that found ERs are present in colorectal tumors
and human colonic cancer cell lines at very low levels
[25].
Figure 1 Chromatograms showing the eight quantified endogenous estrogen metabolites for (a) the ovarian cancer cell line SK-OV-3
and (b) the colon cancer cell line HCC-2998. 16-ketoE2, 16-ketoestradiol; 16a-OHE1, 16a-hydroxyestrone; 2-MeOE1, 2-methoxyestrone; 2-
MeOE2, 2-methoxyestradiol; 2-OHE2, 2-hydroxyestradiol; E1, estrone; E2, estradiol; E3, estriol.
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Table 1 Levels of unconjugated endogenous estrogens (picograms) found in NCI-60 cell lines
Cancer Cell Line E3 16aOHE1 16-epiE3 2MeOE1 2MeOE2 E1 E2 2OHE1 2OHE2 Total
Breast T-47D 0.80 0.03 0.33 2.70 0.54 3.65 87.37 NF 7.30 102.72
(0.07) (0.00) (0.04) (0.34) (0.10) (0.06) (2.69) NF (1.22) (3.18)
Breast Hs-578T 0.43 0.03 0.22 0.62 0.94 8.13 74.11 NF 5.86 90.35
(0.06) (0.00) (0.05) (0.07) (0.17) (0.98) (9.94) NF (0.83) (11.95)
Breast BT-549 0.58 0.02 0.06 0.65 0.45 8.45 58.97 NF 6.03 75.22
(0.10) (0.00) (0.03) (0.10) (0.02) (1.20) (11.51) NF (1.26) (14.15)
Breast MDA-MB-231 0.90 0.02 0.57 1.78 0.35 6.30 36.73 NF 2.55 49.21
(0.07) (0.00) (0.05) (0.24) (0.05) (0.37) (2.41) NF (0.33) (2.71)
Breast MCF-7 0.40 0.04 0.28 2.12 5.38 7.70 80.75 NF 1.76 98.42
(0.03) (0.00) (0.06) (0.23) (0.47) (0.71) (14.44) NF (0.06) (13.04)
CNS SF-295 0.24 0.04 0.12 0.93 0.81 6.79 41.51 NF 7.01 57.44
(0.03) (0.00) (0.01) (0.07) (0.12) (0.93) (2.57) NF (1.03) (3.25)
CNS SF-539 0.82 0.11 NF 1.73 1.22 26.24 175.50 NF 27.11 232.78
(0.10) (0.02) NF (0.13) (0.08) (2.01) (13.14) NF (2.78) (14.43)
CNS SF-268 0.35 0.04 0.31 0.43 0.26 2.69 24.68 NF 7.67 36.42
(0.01) (0.00) (0.03) (0.05) (0.01) (0.10) (1.33) NF (0.96) (2.21)
CNS U251 0.35 0.29 0.21 1.19 0.31 4.54 41.06 NF 12.61 60.55
(0.04) (0.03) (0.02) (0.11) (0.04) (0.21) (4.27) NF (1.22) (5.01)
CNS SNB-19 0.31 0.02 0.08 1.27 0.55 5.09 29.34 NF 3.63 40.29
(0.05) (0.00) (0.01) (0.14) (0.09) (0.64) (2.31) NF (0.25) (3.45)
CNS SNB-75 0.30 0.04 0.10 1.46 0.56 13.15 94.94 NF 2.23 112.79
(0.04) (0.00) (0.01) (0.23) (0.03) (0.57) (1.97) NF (0.24) (1.80)
Colon SW-620 0.75 0.08 0.28 1.70 1.39 0.44 1.31 NF 2.68 8.63
(0.11) (0.01) (0.05) (0.14) (0.23) (0.05) (0.09) NF (0.31) (0.61)
Colon HCT-116 0.12 0.02 0.27 1.40 0.80 0.45 2.17 NF 0.33 5.58
(0.02) (0.00) (0.04) (0.06) (0.08) (0.04) (0.13) NF (0.03) (0.11)
Colon COLO-205 0.33 0.07 0.19 0.57 0.76 1.12 50.44 NF 15.20 68.69
(0.02) (0.01) (0.02) (0.07) (0.07) (0.08) (4.57) NF (0.77) (5.22)
Colon KM12 0.55 0.04 0.31 1.09 0.44 0.14 1.77 NF 0.73 5.06
(0.06) (0.00) (0.04) (0.10) (0.09) (0.01) (0.12) NF (0.13) (0.49)
Colon HT29 0.51 0.03 0.51 1.12 0.28 1.90 30.71 NF 0.51 35.56
(0.01) (0.00) (0.06) (0.12) (0.03) (0.10) (1.12) NF (0.05) (0.90)
Colon HCT-15 28.10 0.40 1.08 0.87 0.29 0.88 12.25 NF 3.75 47.62
(1.54) (0.06) (0.04) (0.09) (0.03) (0.10) (1.22) NF (0.36) (3.05)
Colon HCC-2998 0.88 0.10 0.45 3.10 0.92 17.10 209.34 NF 4.29 236.18
(0.05) (0.01) (0.07) (0.05) (0.17) (0.08) (13.95) NF (0.14) (14.05)
Leukemia HL-60 3.89 0.03 0.29 1.58 3.15 18.78 36.61 NF 16.50 80.83
(0.02) (0.00) (0.01) (0.11) (0.10) (2.39) (2.70) NF (2.81) (2.39)
Leukemia CCRF-CEM 0.41 0.04 0.06 0.66 1.33 1.18 3.48 NF 1.16 8.31
(0.07) (0.00) (0.02) (0.04) (0.10) (0.12) (0.50) NF (0.10) (0.91)
Leukemia K562 0.42 0.02 0.21 0.57 2.23 0.56 13.88 NF 1.16 33.14
(0.07) (0.00) (0.04) (0.06) (0.07) (0.06) (1.75) NF (0.11) (1.24)
Leukemia MOLT-4 0.30 0.08 0.13 0.55 0.77 2.04 7.77 NF 0.75 12.37
(0.04) (0.01) (0.01) (0.04) (0.07) (0.37) (1.14) NF (0.09) (1.53)
Leukemia RMPI-8226 0.93 0.11 0.59 2.04 3.60 182.06 753.45 NF 2.93 945.71
(0.07) (0.02) (0.11) (0.30) (0.16) (5.19) (48.20) NF (0.22) (52.18)
Leukemia SR 4.67 0.06 0.80 3.24 1.45 6.67 26.39 NF 1.22 44.51
(0.53) (0.01) (0.15) (0.51) (0.22) (0.47) (1.38) NF (0.19) (2.00)
Melanoma MDA-MB-435 0.37 0.22 0.09 0.61 3.65 1.77 14.24 NF 2.82 23.77
(0.03) (0.04) (0.02) (0.11) (0.76) (0.18) (0.91) NF (0.32) (1.05)
Melanoma SK-MEL-28 0.82 0.05 0.27 3.83 5.41 21.50 146.59 NF 27.77 206.24
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Table 1 Levels of unconjugated endogenous estrogens (picograms) found in NCI-60 cell lines (Continued)
(0.03) (0.01) (0.02) (0.33) (0.99) (2.12) (15.34) NF (2.17) (16.78)
Melanoma UACC-257 1.20 0.36 0.37 0.74 7.00 36.36 130.70 NF 2.50 179.23
(0.23) (0.07) (0.05) (0.10) (0.78) (2.41) (4.37) NF (0.22) (6.37)
Melanoma LOX IMVI 0.93 0.07 0.44 1.33 1.01 0.35 12.10 NF 8.26 24.49
(0.11) (0.01) (0.07) (0.06) (0.07) (0.02) (0.55) NF (0.64) (0.50)
Melanoma UACC-62 0.20 0.30 0.06 1.41 1.47 17.49 98.71 NF 1.62 121.27
(0.03) (0.04) (0.01) (0.06) (0.25) (0.21) (4.61) NF (0.30) (4.82)
Melanoma SK-MEL-2 1.56 1.60 0.38 2.21 0.62 6.66 50.93 NF 2.90 66.86
(0.15) (0.08) (0.07) (0.05) (0.08) (0.40) (5.84) NF (0.33) (6.40)
Melanoma SK-MEL-5 0.38 0.38 0.13 14.84 0.52 11.64 72.02 NF 3.83 103.75
(0.03) (0.05) (0.02) (0.47) (0.08) (0.31) (4.06) NF (0.50) (5.25)
Melanoma MALME-3M 0.36 0.06 0.32 3.88 0.45 1.26 94.27 NF 1.30 101.90
(0.03) (0.01) (0.05) (0.26) (0.06) (0.05) (0.88) NF (0.13) (1.13)
Melanoma M14 1.33 0.05 0.18 1.24 0.69 1.21 13.95 NF 1.90 20.55
(0.06) (0.00) (0.02) (0.11) (0.11) (0.09) (0.50) NF (0.28) (0.91)
NSCL A549 0.56 0.04 0.54 1.04 1.18 2.95 17.01 NF 2.19 25.51
(0.06) (0.00) (0.05) (0.05) (0.07) (0.27) (0.86) NF (0.24) (1.18)
NSCL EKVX 1.70 0.31 0.92 1.10 7.16 15.16 125.95 NF 4.53 156.83
(0.06) (0.05) (0.01) (0.12) (0.72) (1.13) (13.92) NF (0.47) (12.21)
NSCL HOP-62 1.48 0.08 0.78 2.37 4.70 6.19 25.45 NF 13.29 54.33
(0.24) (0.01) (0.14) (0.40) (0.44) (1.18) (1.85) NF (1.56) (5.04)
NSCL NCI-H23 1.08 0.29 0.39 6.10 0.92 8.03 90.47 NF 15.79 123.07
(0.05) (0.04) (0.08) (0.43) (0.05) (0.64) (2.81) NF (2.87) (3.46)
NSCL NCI-H460 0.18 0.05 0.15 1.36 1.15 4.03 59.76 27.89 2.21 96.78
(0.01) (0.01) (0.00) (0.23) (0.04) (0.06) (3.33) (0.32) (0.12) (3.69)
NSCL NCI-H226 0.29 0.07 0.13 0.50 0.61 25.40 181.13 NF 21.63 229.75
(0.02) (0.01) (0.01) (0.02) (0.07) (1.05) (7.48) NF (0.69) (8.87)
NSCL HOP-92 0.33 0.03 0.43 0.55 0.24 4.87 34.58 NF 2.20 43.24
(0.01) (0.00) (0.08) (0.03) (0.04) (0.28) (1.51) NF (0.24) (1.43)
NSCL NCI-H522 0.18 0.03 0.06 1.38 0.31 4.25 32.36 NF 1.55 40.12
(0.02) (0.00) (0.01) (0.08) (0.04) (0.36) (2.39) NF (0.31) (2.58)
NSCL NCI-H322M 0.19 0.04 0.13 0.80 0.45 0.72 7.01 NF 1.29 10.62
(0.02) (0.00) (0.01) (0.06) (0.04) (0.08) (0.27) NF (0.12) (0.13)
Ovarian OVCAR-3 0.50 0.07 0.34 0.97 3.70 5.37 26.60 NF 5.47 43.02
(0.05) (0.01) (0.04) (0.09) (0.54) (0.73) (1.63) NF (0.81) (3.21)
Ovarian OVCAR-5 0.16 0.03 0.13 1.26 0.33 12.85 107.47 NF 1.57 123.79
(0.00) (0.00) (0.02) (0.17) (0.05) (0.33) (5.55) NF (0.14) (5.89)
Ovarian IGR-OV1 0.15 0.04 0.11 0.73 2.54 4.00 29.72 NF 0.66 37.94
(0.01) (0.00) (0.00) (0.01) (0.36) (0.15) (0.70) NF (0.06) (1.10)
Ovarian NCI/ADR-RES 1.33 0.15 0.44 2.54 2.92 10.46 75.10 NF 4.61 97.56
(0.08) (0.02) (0.04) (0.28) (0.14) (0.31) (0.47) NF (0.28) (0.06)
Ovarian SK-OV-3 1.78 0.13 0.39 0.73 0.55 12.26 132.33 NF 4.18 152.36
(0.23) (0.02) (0.03) (0.09) (0.10) (0.25) (9.43) NF (0.63) (9.94)
Ovarian OVCAR-8 0.44 0.13 0.15 2.10 0.35 5.12 38.83 NF 3.61 50.73
(0.02) (0.03) (0.03) (0.17) (0.06) (0.22) (1.01) NF (0.58) (1.56)
Ovarian OVCAR-4 0.43 0.06 0.31 3.90 0.43 19.79 139.32 NF 4.69 168.93
(0.02) (0.01) (0.02) (0.06) (0.07) (1.06) (2.84) NF (0.46) (2.82)
Prostate PC-3 0.15 0.03 0.20 1.05 2.33 7.63 41.94 NF 0.63 53.96
(0.02) (0.00) (0.03) (0.05) (0.14) (0.56) (2.30) NF (0.07) (2.90)
Prostate DU145 0.55 0.04 0.42 2.22 0.71 4.94 27.78 NF 2.55 39.22
(0.05) (0.00) (0.05) (0.16) (0.10) (0.29) (1.02) NF (0.23) (1.06)
Renal UO-31 0.30 0.13 0.33 1.36 1.66 5.05 22.94 NF 2.45 34.22
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As with E2, the leukemic cell line RPMI-8226 con-
tained the highest levels of E1 of the NCI-60 cell lines
(Figure 3a). The amount measured in this cell line was
more than five-fold higher than that found in the cell
line (melanoma UACC-257) containing the next highest
levels of E1. Again, none of the five breast cancer cell
lines tested was amongst the top ten E1-containing cells.
The ovarian cancer cell line OVCAR-4 (19.79 pg/106
cells) was sixth on the list of cell lines containing the
most E1. Two non-small cell lung carcinoma cell lines
(EKVX and NCI-H226) were amongst the top ten in
both E1 and E2 levels. This result is interesting consider-
ing that females that never smoked are far more likely
to develop lung carcinoma than never-smoked males,
suggesting a gender difference exists in the clinical and
pathophysiology of lung cancer [21]. Recent studies
showing aromatase-dependent synthesis of estrogens in
situ in male and female lung cancers suggest that estro-
gens may contribute to the manifestation and progres-
sion of lung carcinoma [26-28].
Cell lines with the lowest E1 levels are shown in
Figure 3b. COLO-205 was included along with the four
colon cancer cell lines that were amongst the ten con-
taining the lowest E1 levels (HCT-116, HCT-15, KM12,
and SW-620). Their E1 levels ranged from 0.14 to 1.12
pg/106 cells. The levels of E1 found in KM12 colon can-
cer cells was approximately 1,300-fold less than that
found in RPMI-8226 leukemia cells. Two leukemia cell
lines, CCRF-CEM and K562, which were amongst those
possessing the lowest E2 levels, also contained low E1
levels.
To identify general trends within the various cell lines
tested, the means and standard deviations (SDs) of the
total EM levels found in the cell types analyzed. As
shown in Table 2, the leukemia cell lines had the highest
overall mean total EM values (187.5 pg/106 cells). This
value was almost twice as high as the cell types with the
next highest total EM levels. Ovarian (96.33 pg/106 cells)
and breast (83.18 pg/106 cells) cancer cells, which are
commonly associated with estrogens, contained the sec-
ond and sixth highest levels of total EMs. In fact, five of
the cancer cell lines (ovarian, melanoma, CNS, NSCL,
and breast) had total EM levels between 80 and 100 pg/
106 cells. A noticeable feature of Table 2 are the very
high SDs, but in particular that for the leukemia cell
lines. To further explore what contributed to this high
SD, the highest and lowest total EM levels measured for
the individual cell lines in the different cell types were
eliminated and the mean and SD values were recalcu-
lated. The mean EM levels for the leukemia cell lines
after eliminating the cell lines with the highest and lowest
concentrations was 42.71 pg/106 cells with a SD of 28.68;
dropping their overall rank from first to sixth. The cell
types having the three highest EM levels after eliminating
the cell lines with the highest and lowest concentrations
were (in order) ovarian (93.29 pg/106 cells, SD = 46.84),
melanoma (88.75 pg/106 cells, SD = 55.53), and breast
(88.00 pg/106 cells, SD = 11.78).
The finding that the melanoma cell lines contained
relatively high levels of endogenous estrogen and EMs is
interesting. Two melanoma cell lines in particular, SK-
MEL-28 and UACC-257, were among those containing
the highest levels of E1 (21.50 and 36.36 pg/10
6 cells,
respectively) and E2 (146.59 and 130.70 pg/10
6 cells,
respectively). Only four other cell lines, SF-539 (CNS),
NCI-H226 (NSCL), RMPI-8226 (leukemia) and HCC-
2998 (colon), contained higher levels of total estrogens.
High-affinity E2 receptors have been reported for primary
Table 1 Levels of unconjugated endogenous estrogens (picograms) found in NCI-60 cell lines (Continued)
(0.03 (0.02 (0.02 (0.26 (0.26 (0.60 (1.18 NF (0.15 (0.92
Renal 786-0 0.15 0.02 0.11 0.58 0.16 2.11 23.40 NF 1.54 28.07
(0.02) (0.00) (0.01) (0.05) (0.02) (0.16) (0.14) NF (0.19) (0.17)
Renal SN12C 0.14 0.05 0.27 6.47 1.92 4.02 25.50 NF 0.89 39.25
(0.01) (0.01) (0.02) (0.29) (0.17) (0.07) (0.97) NF (0.05) (0.96)
Renal CAKI-1 0.54 0.16 0.13 4.76 0.49 7.57 81.60 NF 6.52 101.77
(0.05) (0.03) (0.03) (0.42) (0.07) (0.61) (1.42) NF (0.79) (2.29)
Renal RXF-393 0.27 0.03 0.09 0.47 0.44 0.34 14.48 NF 1.41 17.54
(0.04) (0.00) (0.02) (0.09) (0.04) (0.04) (0.39) NF (0.13) (0.38)
Renal TK-10 0.65 0.25 0.42 2.54 0.58 7.87 37.29 NF 6.25 55.86
(0.06) (0.04) (0.02) (0.24) (0.06) (0.22) (3.96) NF (0.60) (4.27)
Renal A498 0.53 0.02 0.16 0.29 0.50 3.05 37.53 NF 2.58 44.65
(0.04) (0.00) (0.00) (0.03) (0.07) (0.29) (1.09) NF (0.37) (1.45)
Renal ACHN 0.43 0.08 0.19 1.25 0.39 6.17 39.27 NF 3.40 51.17
(0.06) (0.01) (0.02) (0.16) (0.06) (0.74) (1.96) NF (0.28) (2.51)
Data are expressed as mean (standard deviation) of three replicated analyses of 106 cells. E3, estriol; 16aOHE1, 16a-hydroxyestrone; 16-epiE3, 16-epiestriol;
2MeOE1, 2-methoxyestrone; 2MeOE2, 2-methoxyestradiol; E1, estrone; E2, 17b-estradiol; 2OHE1, 2-hydroxyestrone; 2OHE2, 2-hydroxyestradiol; CNS, central nervous
system; NF, not found; NSCLC, non-small cell lung carcinoma.
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human melanomas [29] and patients expressing these
receptors seem to have a better prognosis, suggesting E2
may inhibit the growth of these melanoma tumors [30].
While previous studies have identified the classical ER in
only a small percentage of human melanomas via immu-
nohistochemistry [30], the low affinity type II ER has
been characterized in a variety of human melanomas
[31]. This receptor has the same affinity as the classical
receptor and also binds tamoxifen. Treating SK-Mel 23
melanoma cells with E2 has been shown to inhibit their
growth, while pre-treating the cells with tamoxifen (an
anti-estrogen) blocks the effects of E2 [32]. The preva-
lence of E2 within the melanoma cell lines may prevent
uncontrolled cell proliferation by acting back upon the
cells and binding to the type II ER.
In general, unconjugated E3, 16aOHE1, and 16-epiE3
were less abundant except for in HCT-15 colon tumor
cells, which had a greater amount of E3 than E2. The
catechol estrogen 2-OHE2 was the only catechol estro-
gen detected in the tumor cell lines, except for the
NSCL cancer cell line NCI-H460, which also contains a
relatively high level of 2-OHE1 (Table 1). No unconju-
gated 4-hydroxy catechol estrogens were detected in any
of the NCI-60 tumor cells. This result is likely due to
the fact that 4-hydroxy catechol estrogens are quickly
transformed into other reactive species such as their
quinones and semi-quinones, which could damage DNA
and lead to tumor initiation [2,33,34]. In contrast, 2-
hydroxy-catechol estrogens largely form stable conju-
gates such as 2-MeOHE1 and 2-MeOHE2. Significant
Figure 2 Cell lines containing the highest and lowest 17b-estradiol (E2) levels within the NCI-60 panel. (a) Cell lines with the highest E2
levels; (b) cell lines with the lowest E2 levels.
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Figure 3 Cell lines containing the highest and lowest estrone (E1) levels within the NCI-60 panel. (a) Cell lines with the highest E1 levels;
(b) cell lines with the lowest E1 levels.
Table 2 Means and standard deviations of total estrogen levels measured in cell types within the NCI-60 cell line
panel
Mean SD Mean (-high/low)* SD (-high/low)*
Breast 83.18 21.70 88.00 11.78
CNS 90.05 75.07 67.77 31.31
Colon 58.19 82.12 33.21 26.64
Leukemia 187.48 372.4 42.71 28.67
Melanoma 94.23 67.69 88.75 55.49
NSCL 86.69 71.98 77.13 49.25
Ovarian 96.33 54.00 93.49 46.84
Prostate 46.59 10.42 NA NA
Renal 46.57 25.49 42.20 10.44
Mean and standard deviation (SD) are presented for all values within specific cell types and for values after eliminating cell lines with the highest and lowest
total estrogen levels. CNS, central nervous system; NSCLC, non-small cell lung carcinoma. *Mean and standard deviation calculated after removing cell lines
containing highest and lowest total measured estrogen levels. NA, only two prostate cell lines were included in NCI-60 cell lines analyzed.
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levels of both of these EMs were found in all NCI-60
cell lines tested in this study.
This study measured the unconjugated levels of endo-
genous estrogens and EMs in the NCI-60 cell panel. From
our previous experience, if we had measured the conju-
gated levels by adding a sulfatase/glucoronidase enzyme to
deconjugate sulfated and glucoronidated molecules prior
to LC-MS2 analysis, we would expect to see a large
increase in the levels of every metabolite that was routinely
detected. We would also expect that 16-epiE3, 17-epiE3, 4-
MeOE1, 3-MeOE1, 4-MeOE2, 2-OHE1, and 4-OHE1 would
also be detectable. Our studies analyzing serum have
shown that endogenous estrogens and EMs exist primarily
(that is, 90%) in the conjugated forms in the circulation
[20]. While this disparity between conjugated and uncon-
jugated forms of these steroid hormones may not be as
large in cells, we predict that a large amount of endogen-
ous estrogens and EMs exist within cells in their conju-
gated forms. It is interesting to note that when we analyze
serum, only E1, E2, E3, 2-MeOHE1 and 2-MeOHE2 are
detected in their unconjugated forms [20]. In the NCI-60
cell lines we were able to also routinely detect 16-aOHE1,
16-epiE3, and 2-OHE2. Unfortunately, it is difficult to
directly compare the estrogen and EM levels as the cell
line concentrations are recorded in pg/106 cells, while
those in serum are measured as pg/ml. The fact that more
compounds are detected in their unconjugated forms in
the cell lines, however, suggests that, in general, the con-
centrations of estrogens and EMs are higher in cells than
in the circulation.
To determine if ER status correlates with the levels of
estrogens and EMs identified in the various cell lines,
we compare our data to that published by Holbeck et
al. [35], who measured the mRNA levels of 48 nuclear
receptors in 51 of the NCI-60 cell lines. The mRNA
levels of ERa for nine of the cell lines that were found
to contain the highest E2 levels were measured in this
study. Of these, detectable ERa levels were found for
SKOV-3, OVCAR-4, UACC-257, SK-MEL-28, and SF-
539 cell lines. No ERa mRNA was detected for HCC-
2998, NCI-H226, EKVX, and OVCAR-5 cell lines. The
cell lines with the highest levels of ERa mRNA were
SK-OV-3, and two breast cancer cell lines, MCF-7 and
T-47D. Of these, only SK-OV-3 was among the cell
lines containing the highest amounts of E2. We also
compared the ERa and E2 levels within the nine mela-
noma cell lines analyzed in both studies. In this case,
the six melanoma cell lines with detectable levels of
ERa mRNA (SK-MEL-28, UACC-257, UACC-62, SK-
MEL-2, SK-MEL-5, and MALME-3M) contained the
highest amounts of E2 within that group. The melanoma
cell lines containing the lowest E2 concentrations (M14,
LOX IMVI, and MDA-MB-435) did not show detectable
levels of ERa. Overall, there is no obvious correlation
between ERa and E2 levels; however, only about 25% of
the cell lines had detectable levels of ERa whereas E2
could be measured in every one.
Conclusions
This study utilized an LC-MS2 approach with the cap-
ability of measuring up to 15 different EMs to measure
the levels of endogenous estrogens within the NCI-60
cell lines. Eight of the measured endogenous estrogens
were consistently observed in all of the NCI-60 cell
lines, providing an unprecedented view of these metabo-
lites within these cancer cell lines. What is particularly
striking is that the levels of EMs in well-known estro-
gen-dependent cancers such as ovarian and breast were
not substantially greater than those found in other types
of cancer cell lines. In fact, none of the breast cancer
cell lines were amongst the top ten that contained the
highest levels of E1 or E2. Cell lines not generally asso-
ciated with estrogens, such as leukemia, colon, CNS,
and NSCL, were found to have appreciable levels of
these metabolites. The broad presence of EMs within
the NCI-60 cell lines suggests that many cancers outside
of the reproductive system may respond to treatments
with anti-estrogens such as tamoxifen, toremifene, and
fulvestrant. Considering technologies for measuring
estrogen levels in biological samples is considerably
improved, it is now worth the effort to test various
tumors for the levels of these metabolites.
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